Attenuation of CXCR4 responses by CCL18 in acute lymphocytic leukemia B cells.
CCL18 and CXCL12 are homeostatic chemokines with high constitutive concentrations in serum. Elevated levels of CCL18 have been described in various diseases including childhood acute lymphocytic leukemia (ALL) but its functions remain poorly characterized. Its receptor has not been identified, but functional cellular responses like lymphocyte chemotaxis have been described. CXCL12 is a pivotal chemokine for hematopoiesis and B cell homing processes. We demonstrate that CCL18 interferes with CXCL12-mediated pre-B ALL cell activation. CXCL12-induced calcium mobilization, chemotaxis, pseudo-emperipolesis and cellular proliferation could be significantly reduced by CCL18 in pre-B ALL cell lines. The results could be observed in primary cells from patients suffering from pre-B ALL, but not in cells from patients suffering from common ALL. Direct effects of CCL18 on the receptor for CXCL12, CXCR4, could be excluded. Moreover, we found that CCL18 modulations of CXCL12-induced responses are mediated through the chemokine-like receptor GPR30. CCL18 bound to GPR30 expressing cells, and antibodies against GPR30 abolished this binding as well as CCL18-mediated functional effects. We also observed that, CCL18 interferes with the activation of GPR30 by previously identified ligands (17β-estradiol and chemical agonists). We therefore suggest that CCL18 is an important modulator of CXCR4-dependent responses in pre-B ALL cells via interactions with GPR30.
Catusse
J
J
Department of Hematology and Oncology, University Clinic of Freiburg, Freiburg, Germany.
Wollner
S
S
Leick
M
M
Schröttner
P
P
Schraufstätter
I
I
Burger
M
M
D000818:Animals; D017209:Apoptosis; D019556:COS Cells; D020013:Calcium Signaling; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D054377:Chemokine CXCL12 / Q000378:metabolism; D019742:Chemokines, CC / Q000378:metabolism*; D002634:Chemotaxis, Leukocyte; D002522:Chlorocebus aethiops; D004958:Estradiol / Q000378:metabolism; D004965:Estrogen Antagonists / Q000494:pharmacology; D006801:Humans; D008024:Ligands; D008213:Lymphocyte Activation; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology* / Q000473:pathology; D054448:Precursor Cells, B-Lymphoid / Q000187:drug effects / Q000276:immunology* / Q000473:pathology; D019718:Receptors, CXCR4 / Q000378:metabolism*; D011960:Receptors, Estrogen; D043562:Receptors, G-Protein-Coupled / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D011994:Recombinant Proteins / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D014162:Transfection
C111792:CCL18 protein, human; C515255:CXCL12 protein, human; C527276:CXCR4 protein, human; D054377:Chemokine CXCL12; D019742:Chemokines, CC; D004965:Estrogen Antagonists; C109584:GPER1 protein, human; D008024:Ligands; D019718:Receptors, CXCR4; D011960:Receptors, Estrogen; D043562:Receptors, G-Protein-Coupled; D011994:Recombinant Proteins; D004958:Estradiol